PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic ® (semaglutide) injection 1 mg in ...

At the meeting of the American College of Cardiology (ACC) held in Chicago from 29 March to 31 March 2025, Novo Nordisk has announced the primary results of the Phase IIIb STRIDE trial investigating ...

AURORA, CO / ACCESS Newswire / September 5, 2025 / The Global PAD Association has presented the 2025 Walking As Therapy Breakthrough Research of the Year award to The STRIDE Trial Research Team led by ...

Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD 1 Based on STRIDE ...